For example, an important difference is that IL-6 blockage is initiated before or at the time of disease development in the mice models of AAA, thereby not truly mimicking the treatment effects expected in humans, in which drugs to block IL-6 pathway would be started after disease onset. Here, IL6 is linked to triple-A syndrome.